Non-Muscle Invasive Bladder Cancer market reached approximately USD 2.35 billion in 2023

The Non-Muscle Invasive Bladder Cancer (NMIBC) market is driven by rising disease prevalence, the entry of premium therapies, and an expanding base of active biopharma companies. High-risk NMIBC contributed the largest share, accounting for USD 1.6 billion of the total market size.

Current treatment approaches include surgery, intravesical BCG immunotherapy, and intravesical chemotherapy. However, only three FDA-approved therapies exist for NMIBC: KEYTRUDA (2020), ADSTILADRIN (2022), and ANKTIVA (2024).

A long-standing global BCG shortage worsened even before the COVID-19 pandemic—has led clinicians to adopt alternative regimens such as gemcitabine + docetaxel. Recent collaboration between the Serum Institute of India and ImmunityBio aims to stabilize BCG supply through expanded production and development of improved recombinant BCG strains.

The NMIBC pipeline is robust, featuring promising candidates such as CG0070, Sasanlimab, EG-70, UGN-102, Ruvidar, TAR-200, and TAR-210. Most ongoing R&D focuses on intermediate- and high-risk NMIBC, with limited activity in low-risk disease.

Among emerging therapies, UGN-102 shows strong clinical evidence and, if approved, could transform treatment for low-grade, intermediate-risk NMIBC by offering a non-surgical, minimally invasive alternative to repeated resections. Its early development timeline may position it favorably ahead of competitors entering the same segment.

As more novel treatments with different mechanisms emerge, selecting optimal therapy sequences becomes increasingly complex. Personalized treatment strategies guided by biomarkers and patient-specific factors will be essential.

Innovative drug delivery technologies such as TAR-200 and TAR-210 using hyperthermia or electromotive administration - are also enhancing intravesical drug absorption and improving therapeutic outcomes.

The Non-Muscle Invasive Bladder Cancer (NMIBC) market is undergoing a period of rapid transformation, fueled by growing disease prevalence, breakthrough clinical developments, and an expanding portfolio of innovative therapeutics. According to DelveInsight’s latest publication, “Non-Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast—2034,” the NMIBC market is set to witness substantial growth across the seven major markets (7MM), including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Robust Industry Participation Shaping the Competitive Landscape

The NMIBC treatment landscape is supported by a strong group of leading biopharmaceutical innovators. Key companies driving advancements include:

CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Binhui Biopharmaceutical, SURGE Therapeutics, AstraZeneca, ImmunityBio, Inc., Guarionex J. Decastro, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Bristol Myers Squibb, Asieris Pharmaceuticals, and others.

These companies collectively contribute to the development of targeted, immune-based, gene therapy, and intravesical treatment modalities designed to optimize patient outcomes while addressing unmet clinical needs.

Pipeline Highlights: Transformational Clinical Advances in NMIBC

The NMIBC pipeline is witnessing promising progress, marked by multiple recent clinical updates across various treatment modalities:

Pfizer's CREST Trial Achieves Primary Endpoint (January 2025)

Pfizer announced positive topline results from its Phase 3 CREST trial evaluating sasanlimab—an investigational anti–PD-1 monoclonal antibody—combined with BCG for high-risk, BCG-naïve NMIBC. The combination therapy demonstrated statistically significant improvements in event-free survival (EFS) versus BCG alone, underscoring the therapy’s clinical and immunological potential.

TYRA-300 IND Cleared by FDA (January 2025)

Tyra Biosciences received IND clearance for TYRA-300, enabling initiation of a Phase 2 trial for low-grade, intermediate-risk NMIBC. Targeting FGFR biology with next-gen precision oncology, this therapy aims to strengthen treatment options for patients who remain underserved in existing care pathways.

Aura Biosciences’ Early Phase 1 Results for AU-011 (October 2024)

Aura reported compelling early clinical data for bel-sar (AU-011) in its ongoing Phase 1 NMIBC study. Among patients receiving light-activated therapy, 80% of low-grade cases achieved a complete response, along with tumor reduction observed in high-grade cases. The therapy’s novel targeted approach and strong safety profile suggest meaningful potential as a next-generation intervention.

UroGen Pharma Launches Phase III UTOPIA Study (October 2024)

UroGen initiated dosing in its pivotal UTOPIA Phase III clinical trial evaluating UGN-103 (mitomycin) for low-grade, intermediate-risk NMIBC. Designed as a chemoablative intravesical therapy, UGN-103 aims to address unmet needs among patients who may require ongoing cystoscopic surveillance.

These developments reflect the NMIBC market’s shift towards more effective, less invasive, and precision-driven therapies.

Epidemiology Insights: Growing Patient Burden Across the 7MM

DelveInsight’s epidemiology analysis reveals a rising prevalence of NMIBC across major markets.

Key Epidemiology Findings:

• The United States reported approximately 600,000 prevalent NMIBC cases in 2023, the highest among the 7MM.
• In Japan, individuals aged 70–89 accounted for 60% of all NMIBC cases in 2023, highlighting age-associated disease trends.
• Across Europe, NMIBC continues to represent a substantial proportion of the total bladder cancer burden.
• NMIBC accounts for around 75% of all bladder cancer diagnoses, as per the American Urological Association and European Association of Urology.
• Despite BCG’s longstanding role in treatment, 20–40% of patients experience recurrence or persistence, leading to BCG-unresponsive classification (Valenza et al., 2022).
• Among all risk strata, high-risk NMIBC generated the largest market share, with approximately USD 1,600 million in 2023 across the 7MM.

The persistent recurrence rates and age-based vulnerability underscore the urgent need for optimized therapeutic strategies and earlier intervention methods.

Therapeutic Landscape: Multiple Modalities Advancing toward Market Entry

The NMIBC therapeutic pipeline includes an impressive range of targeted agents, immunotherapies, genetic therapies, combination regimens, and intravesical treatments. Key assets include:

• CG0070 (CG Oncology) – Oncolytic immunotherapy
• Sasanlimab (Pfizer) – Anti–PD-1 antibody
• UGN-102 (UroGen Pharma) – Chemoablative intravesical therapy
• TAR-200 (Janssen Research & Development) – Novel drug delivery system
• TARA-002 (Protara Therapeutics) – Investigational immunotherapy
• OH2 Injection (Binhui Biopharmaceutical)
• STM-416 (SURGE Therapeutics)
• Durvalumab (AstraZeneca)
• BCG+N-803 (ImmunityBio)
• Cabazitaxel (Guarionex J. Decastro)
• Cetrelimab (Janssen Research & Development)
• TL-532 (Tollys)
• AU-011 (Aura Biosciences)
• VAX-014 (Vaxiion Therapeutics)
• Pemigatinib (Incyte)
• Erdafitinib (Janssen Pharmaceuticals)
• TLD-1433 (Theralase Technologies)
• Nivolumab (Bristol Myers Squibb)
• APL-1202 (Asieris Pharmaceuticals)

These therapies collectively aim to overcome limitations of existing treatments, reduce recurrence rates, improve bladder preservation, and expand patient eligibility through more personalized interventions.

Market Drivers and Opportunities

Several factors are contributing to the expected market expansion:

Key Market Drivers

• Rising NMIBC prevalence and expanding diagnosed patient pool
• Rapid adoption of precision therapies and novel immunotherapeutic agents
• Increased awareness and improved screening capabilities
• Robust clinical trial activity supported by global pharmaceutical investment

Emerging Opportunities

• Integration of biomarkers for enhanced early diagnosis
• Development of advanced combination therapies with BCG
• Emergence of innovative non-viral gene therapy approaches
• Strong real-world evidence supporting immunotherapeutic strategies

The convergence of these advancements is anticipated to create new commercial opportunities and accelerate the availability of transformative NMIBC treatments.

Scope of the DelveInsight NMIBC Market Report

The comprehensive report covers:

• Study Period: 2020–2034
• Regions: United States, EU4, United Kingdom, Japan
• Market Dynamics: Drivers, barriers, unmet needs, trends
• Pipeline Assessment: Clinical trials, emerging therapies, competitive landscape
• Epidemiology: Prevalence, segmentation, demographics
• Commercial Analysis: Drug uptake, sales forecasts, market share projections
• Competitive Intelligence: SWOT, PESTLE, Porter’s Five Forces, BCG Matrix
• Market Access: Reimbursement insights, pricing strategies

For deeper insights into the market outlook, treatment landscape, and epidemiology trends, access the full report here: Non-Muscle Invasive Bladder Cancer Market Forecast.

About DelveInsight

DelveInsight is a leading healthcare business consulting and market research firm exclusively focused on life sciences. The company provides comprehensive, end-to-end solutions that enable pharmaceutical and biotech organizations to accelerate growth, optimize portfolios, and navigate competitive challenges. DelveInsight’s expertise spans market research, pipeline evaluation, epidemiology forecasting, competitive intelligence, and strategic consulting.Bottom of Form